Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer.
Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F; Oslo Breast Cancer Research Consortium (OSBREAC)SauerTorillGeislerJürgenHofvindSolveigBathenTone FBorgenElinEngebråtenOlavFodstadØysteinGarredØysteinGeitvikGry AarumKåresenRolfNaumeBjørnMælandsmoGunhild MariRussnesHege GSchlichtingEllenSørlieThereseLingjærdeOle ChristianSahlbergKristine KleiviSkjervenHelle KristineFritzmanBritt; Ulitsky I, Diederichs S, Wiemann S, Yakhini Z, Kristensen VN, Børresen-Dale AL, Yarden Y. Sas-Chen A, et al. Among authors: nevo n. EMBO Mol Med. 2016 Sep 1;8(9):1052-64. doi: 10.15252/emmm.201606198. Print 2016 Sep. EMBO Mol Med. 2016. PMID: 27485121 Free PMC article.
SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.
Roth L, Srivastava S, Lindzen M, Sas-Chen A, Sheffer M, Lauriola M, Enuka Y, Noronha A, Mancini M, Lavi S, Tarcic G, Pines G, Nevo N, Heyman O, Ziv T, Rueda OM, Gnocchi D, Pikarsky E, Admon A, Caldas C, Yarden Y. Roth L, et al. Among authors: nevo n. Sci Signal. 2018 Jan 30;11(515):eaan0949. doi: 10.1126/scisignal.aan0949. Sci Signal. 2018. PMID: 29382783
Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment.
Lauriola M, Enuka Y, Zeisel A, D'Uva G, Roth L, Sharon-Sevilla M, Lindzen M, Sharma K, Nevo N, Feldman M, Carvalho S, Cohen-Dvashi H, Kedmi M, Ben-Chetrit N, Chen A, Solmi R, Wiemann S, Schmitt F, Domany E, Yarden Y. Lauriola M, et al. Among authors: nevo n. Nat Commun. 2014 Oct 3;5:5073. doi: 10.1038/ncomms6073. Nat Commun. 2014. PMID: 25278152 Free PMC article.
Loss of ovarian function promotes angiogenesis in human ovarian carcinoma.
Schiffenbauer YS, Abramovitch R, Meir G, Nevo N, Holzinger M, Itin A, Keshet E, Neeman M. Schiffenbauer YS, et al. Among authors: nevo n. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13203-8. doi: 10.1073/pnas.94.24.13203. Proc Natl Acad Sci U S A. 1997. PMID: 9371824 Free PMC article.
Vasorin: a newly identified regulator of ovarian folliculogenesis.
Rimon-Dahari N, Heinemann-Yerushalmi L, Hadas R, Kalich-Philosoph L, Ketter D, Nevo N, Galiani D, Dekel N. Rimon-Dahari N, et al. Among authors: nevo n. FASEB J. 2018 Apr;32(4):2124-2136. doi: 10.1096/fj.201700057RRR. Epub 2018 Jan 5. FASEB J. 2018. PMID: 29259033
Overall, our findings reveal that Vasn is a new regulator that exerts an effect on several key ovarian functions, including folliculogenesis, maintenance of the ovarian reserve, and ovulation.-Rimon-Dahari, N., Heinemann-Yerushalmi, L., Hadas, R., Kalich-Philosoph, L., Ket …
Overall, our findings reveal that Vasn is a new regulator that exerts an effect on several key ovarian functions, including folliculogenesis …
108 results